NCT06561425 - A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

274

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

July 1, 2029

Study Completion Date

July 1, 2029

Conditions

Relapsed/Refractory B-cell Non-Hodgkin LymphomaLymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell

Interventions

GENETIC

GLPG5101

Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy

Trial Locations (10)

RECRUITING

Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert

RECRUITING

Antwerp University Hospital, Edegem

RECRUITING

UZ Leuven, Leuven

RECRUITING

CHU De Liège, Liège

RECRUITING

Tufts Medical Center, Boston

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

RECRUITING

Academisch Medisch Centrum, Amsterdam

RECRUITING

Leiden University Medical Center, Leiden

RECRUITING

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam